Novo Nordisk Discloses Insider Share Transactions
Ticker: NONOF · Form: 6-K · Filed: Nov 7, 2024 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulation
Related Tickers: NVO
TL;DR
Novo Nordisk insiders bought/sold shares, check the filing for details.
AI Summary
On November 7, 2024, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This report, filed under Form 6-K, adheres to Article 19 of Regulation No. 596/2014 concerning market abuse.
Why It Matters
This filing provides transparency into the trading activities of company insiders, which can offer insights into their confidence in the company's future performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of insider trading activity and does not contain new financial information or strategic changes.
Key Players & Entities
- NOVO NORDISK A S (company) — Registrant
- Novo Nordisk (company) — Company name
- November 7, 2024 (date) — Filing date and transaction disclosure date
- Article 19 of Regulation No. 596/2014 (regulation) — Governing regulation for disclosures
FAQ
What type of transactions are being disclosed by Novo Nordisk?
The filing discloses transactions in Novo Nordisk shares made by the company's board members, executives, and their associated persons.
What regulation governs these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
When was this company announcement made?
The company announcement was made on November 7, 2024.
What is the form type filed with the SEC?
The form type filed is a 6-K.
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2024-11-07 15:06:46
Filing Documents
- f6k_110724.htm (6-K) — 24KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-24-006117.txt ( ) — 164KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: November 7, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer